Insulin degludec, the new generation basal insulin or just another basal insulin?

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 5, Issue , 2012, Pages 31-37

  Nasrallah, Sami N ^a   Raymond Reynolds, L ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Basal insulin; Insulin analogs; Insulin degludec; Insulin degludec70 aspart30 ; Long acting insulin analogs

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN RECEPTOR; ISOPHANE INSULIN; SOMATOMEDIN C RECEPTOR;

CARCINOGENICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; WEIGHT GAIN;

EID: 84863956945     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S9494     Document Type: Review

References (27)

1. Simon AC, DeVries JH. The future of basal insulin supplementation. Diabetes technology and therapeutics. Jun 2011;13 Suppl 1:S103-8.
2. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. Mar 12, 2011;377(9769):924-31.
3. Ib Jonassen SH, Ulla Ribel, Thomas Hoeg-Jensen, et al. Insulin degludec is a new generation ultra-long acting bsal insulin with a unique mechansim of protraction based on multi-hexamer formation. 2010.
4. Erica Nishimura ASOr, Bo Flack Hansen, Carsten Stidsen, et al. Insulin degludec is a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potentital. 2010.
5. Luigi F. Meneghini SLA, Stephen Bain, et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with type 2 diabetes. 2011.
6. Peter Kurtzhals TH, Holger M. Strauss, Susanne G. B[Oslash]ttcher, Charlotte Granhall, Hanne Haahr, Ib Jonassen. Multi-Hexamer Formation is the Underlying Mechanism behind the Ultra-Long Glucose-Lowering Effect of Insulin Degludec. 2011.
7. Owens DR. Insulin preparations with prolonged effect. Diabetes Technology and Therapeutics. Jun 2011;13 Suppl 1:S5-14.
8. Danne T, Bolinder J. New insulins and insulin therapy. International Journal of Clinical Practice Supplement. Feb 2011;(170):26-30.
9. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. Mar 2011;34(3): 661-5.
10. Luigi F. Meneghini PDH, Ulrich Wendisch, Robert E. Ratner, Lars A. Endhal, Thue Johansen, Karsten Lyby, Johan H. Jendle, Anthony P. Roberts, J. Hans Devries, K[Aring]re I. Birkeland. Insulin Degludec, a New Generation Ultra-Long Acting Insulin, in a Mealtime Basal Regimen in People with Type 1 Diabetes: Comparison to insulin Glargine. 2010.
11. Simon Heller AMOF, Huiling Pei, David Russell-Jones. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basalbolus trial in type 1 diabetes. 2011.
12. Bernard Zinman GF, Paturi V. Rao, Nihal Thomas, et al. Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3 times weekly in people with type 2 diabetes: comparison to insulin glargine. 2010.
13. Heise T, Tack CJ, Cuddihy R, et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. Mar 2011;34(3):669-74.
14. Tim Heise CT, Bob Micheal Cuddihy, Jaime Davidson, et al. Once-daily use of a new generation ultra-long acting basal insulin with a bolus boost in insulin-naive subjects with type 2 diabetes: comparison with insulin. 2010.
15. Allan Vaag LAL, Edward Franek, Jianping Weng, et al. Use of a new basal insulin with a bolus boost (idegasp) in type 2 diabetes: comparison with biphasic insulin aspart 30 (BIAap 30). 2011.
16. Alan J, Garber ABK, Anne Marrie O, Francisco, Lars Endahl, Priscilla A. Hollander insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with type 2 diabetes. 2011.
17. Irl B, Hirsch EF, Jean-Pierre Courreges, Henriette Mersebach, Patrik Dykiel, Bruce W. Bode efficacy and safety of a new basal insulin with a bolus boost (IDegasp) used once daily in combination with insulin aspart (IAsp) in people with type 1 diabetes. 2011.
18. Tim Heise LH, Leszek Nosek, Andre Feldmann, S[Oslah]ren Rasmussen, Hanne Haahr. The pharmacodynamic variability of insulin degludec isconsistently lower than insulin glargine over 24 hours at steady state. 2011.
19. Danne T, Bolinder J. New insulins and insulin therapy. International Journal of Clinical Practice. Feb 2011;65 Suppl 170:26-30.
20. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clinical Therapeutics. Nov 2008;30(11):1976-87.
21. al Ne. IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 2011.
22. Hirsch IB. Insulin analogues. The New England Journal of Medicine. Jan 13, 2005;352(2):174-83.
23. Hedrington MS, Pulliam L, Davis SN. Basal insulin treatment in type 2 diabetes. Diabetes Technology and Therapeutics. Jun 2011;13 Suppl 1: S33-42.
24. Yn Bi XL, Daizhi Yang, Yuantao Hao, Hua Liang, Dalong Zhu, Jianping Weng. Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses. Journal of Diabetes Investigation. 2011.
25. Reynolds LR. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary. Postgraduate Medicine. Jan 2010;122(1):201-3.
26. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. Jan 2012;55(1):51-62.
27. Blin P, Lassalle R, Dureau-Pournin C, et al. Insulin glargine and risk of cancer: A cohort study in the French National Healthcare Insurance Database. Diabetologia. Mar 2012;55(3):644-53.